Q-omics provides the consensus-scored H2AX profile across patient tissues and cancer cell-line models. H2AX expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H2AX is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, H2AX RNA expression shows 21,352 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where H2AX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AX survival associations across molecular data types. H2AX RNA expression shows survival associations in the most cancer types (30), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AX RNA expression–survival associations across cancer types. High H2AX expression shows unfavorable associations in ACC, KIRC, MESO, LIHC, KIRP and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H2AX RNA expression.
This table summarizes H2AX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for H2AX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AX shows higher tumor expression in BLCA, LUAD, COAD, KIRP, KIRC and HNSC. The BLCA box plot shows higher H2AX RNA expression in tumor versus normal tissue (log2 FC = +2.555, t-test p < 0.001).
This table shows molecular features associated with H2AX in patient tissues and cancer cell lines. In patient samples, H2AX shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
